Q-omics provides the consensus-scored SNHG30 profile across patient tissues and cancer cell-line models. SNHG30 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNHG30 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, SNHG30 RNA expression shows 20,555 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KICH, and LSCC as cancer lineages where SNHG30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG30 survival associations across molecular data types. SNHG30 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG30 RNA expression–survival associations across cancer types. High SNHG30 expression shows unfavorable associations in ACC and LIHC, but favorable associations in LUSC, CHOL, STAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNHG30 RNA expression.
This table summarizes SNHG30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG30 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LIHC, HNSC and BLCA. The KICH box plot shows higher SNHG30 RNA expression in normal versus tumor tissue (log2 FC = −2.316, t-test p < 0.001).
This table shows molecular features associated with SNHG30 in patient tissues and cancer cell lines. In patient samples, SNHG30 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
